Bivalirudin for blood thinning in ECMO patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if bivalirudin is a safe and effective blood thinner for people on ECMO, a machine that helps your heart and lungs. You may be eligible if you need this therapy and have no past reactions to similar medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You are receiving or will receive VA-ECMO or VV-ECMO (heart-lung support).
- Your medical team decides you need a blood thinner and your blood clotting time (APTT) should be kept between 40-60 seconds.
- You must sign a consent form agreeing to participate.
- You cannot have had an allergic reaction to heparin or bivalirudin before.
- You cannot have a history of heparin-induced low platelets (HIT).
- You cannot have been on ECMO for more than 48 hours before joining.
- You cannot be pregnant.
- You cannot have taken part in this study before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.
This Phase 2 trial compares two blood-thinning medicines—bivalirudin and heparin—in people on ECMO (a machine that supports breathing and/or circulation). It aims to see which medicine works better and is safer while you are connected to the ECMO circuit.
This trial studies whether people on a breathing machine called VV-ECMO can be managed without routine blood thinners, to reduce bleeding risk. It is meant for adults with severe lung failure (ARDS) and checks that it is safe for you to avoid anticoagulation.
This study looks at how platelets (the cells that help clot blood) behave in patients on a lung-support machine called ECMO. By taking blood samples, researchers hope to better understand clotting issues that can occur during ECMO support.
This study tests whether a blood thinner called bivalirudin, given during a procedure to open blocked heart arteries (PCI), helps blood flow better in the tiny vessels of the heart afterward. It is for people with a recent unstable heart condition and a high-risk plaque seen on a CT scan.
This trial tests a way to manage blood clotting in patients on ECMO (a machine that helps breathe for very sick patients). It uses a drug called Nafamostat with a lower dose of standard blood thinners, which may reduce bleeding risks.
Hear when a new Extracorporeal Membrane Oxygenation Complication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.